US89377M1099
© PR Newswire
24.12.2025
TMDX
LISTED
NASDAQ
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
ANDOVER, Mass., Dec. 24, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on December 22, 2025, TransMedics granted non-qualified stock options to purchase an aggreg...
Themefolio
Profiler
Peergroup
© PR Newswire
18.11.2025
TMDX
LISTED
NASDAQ
TransMedics to Participate in the Piper Sandler 37th Annual Healthcare Conference
News Preview
ANDOVER, Mass., Nov. 18, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fir...
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2025
TMDX
LISTED
NASDAQ
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
ANDOVER, Mass., Oct. 31, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 27, 2025, TransMedics granted non-qualified s...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
29.10.2025
TMDX
LISTED
NASDAQ
TransMedics Reports Third Quarter 2025 Financial Results
News Preview
ANDOVER, Mass., Oct. 29, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2025....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
15.10.2025
TMDX
LISTED
NASDAQ
TransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025
News Preview
ANDOVER, Mass., Oct. 15, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
TMDX
LISTED
NASDAQ
TransMedics and Mercedes-Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy
News Preview
Modern, purpose-built Mercedez-Benz V-Class fleet to be deployed across four National OCS Program ("NOP") hubs in Italy to support utilization of TransMedics' Organ Care System ("OCS") perfusion technology and increase donor organ utilization for patients in need
TransMedics President and Chief Executive Officer, Waleed Hassanein, M.D., to discu...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
TMDX
LISTED
NASDAQ
TransMedics and Mercedes-Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy
News Preview
Modern, purpose-built Mercedez-Benz V-Class fleet to be deployed across four National OCS Program ("NOP") hubs in Italy to support utilization of TransMedics' Organ Care System ("OCS") perfusion technology and increase donor organ utilization for patients in need
TransMedics President and Chief Executive Officer, Waleed Hassanein, M.D., to discu...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
TMDX
LISTED
NASDAQ
TransMedics to Present at Upcoming September Investor Conferences
News Preview
ANDOVER, Mass., Aug. 25, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management...
Themefolio
Profiler
Peergroup
© PR Newswire
01.08.2025
TMDX
LISTED
NASDAQ
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
ANDOVER, Mass., Aug. 1, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on July 28, 2025, TransMedics granted non-qualified stock options to purchase an aggregate...
Themefolio
Profiler
Peergroup
© PR Newswire
30.07.2025
TMDX
LISTED
NASDAQ
TransMedics Reports Second Quarter 2025 Financial Results
News Preview
ANDOVER, Mass., July 30, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
29.07.2025
TMDX
LISTED
NASDAQ
TransMedics to Present at the Canaccord Genuity 45th Annual Growth Conference
News Preview
ANDOVER, Mass., July 29, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming Canaccord Genuity 45th Annual...
Themefolio
Profiler
Peergroup
© PR Newswire
16.07.2025
TMDX
LISTED
NASDAQ
TransMedics to Report Second Quarter 2025 Financial Results on July 30, 2025
News Preview
ANDOVER, Mass., July 16, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2025 after market close on Wednesd...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
27.05.2025
TMDX
LISTED
NASDAQ
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
ANDOVER, Mass., May 27, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 21, 2025, TransMedics granted non-qualified stock options to purchase an aggregate o...
Themefolio
Profiler
Peergroup
© PR Newswire
20.05.2025
TMDX
LISTED
NASDAQ
TransMedics to Present at Upcoming June Investor Conferences
News Preview
ANDOVER, Mass., May 20, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management i...
Themefolio
Profiler
Peergroup
© PR Newswire
08.05.2025
TMDX
LISTED
NASDAQ
TransMedics Reports First Quarter 2025 Financial Results
News Preview
ANDOVER, Mass., May 8, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
24.04.2025
TMDX
LISTED
NASDAQ
TransMedics to Report First Quarter 2025 Financial Results on May 8, 2025
News Preview
ANDOVER, Mass., April 24, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2025 after market close on Thursda...
Themefolio
Profiler
Peergroup
© BusinessWire
15.04.2025
TMDX
LISTED
NASDAQ
TMDX Deadline Today: Rosen Law Firm Encourages TransMedics Group, Inc. Investors to Secure Counsel Before Important April 15 Deadline in Securities Class Action First Filed by the Firm – TMDX
News Preview
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of TransMedics Group, Inc. (NASDAQ: TMDX) between February 28, 2023 and January 10, 2025, both dates inclusive (the “Class Period”), of the important April 15, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.
So what: If yo...
Themefolio
Profiler
Peergroup
© BusinessWire
15.04.2025
TMDX
LISTED
NASDAQ
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of TransMedics Group
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ: TMDX) and reminds investors of the April 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Fa...
Themefolio
Profiler
Peergroup
© PR Newswire
02.04.2025
TMDX
LISTED
NASDAQ
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
ANDOVER, Mass., April 2, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on March 28, 2025, TransMedics granted non-qualified stock options to purchase an aggregat...
Themefolio
Profiler
Peergroup
© BusinessWire
20.03.2025
TMDX
LISTED
NASDAQ
Kirby McInerney LLP Reminds TransMedics Group, Inc. (TMDX) Investors of Securities Class Action Lawsuit and Encourages Investors to Contact the Firm
News Preview
The law firm of Kirby McInerney LLP reminds investors who purchased TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ:TMDX) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to the securities fraud cl...
Themefolio
Profiler
Peergroup
© BusinessWire
02.03.2025
TMDX
LISTED
NASDAQ
TMDX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that TransMedics Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against TransMedics Group, Inc. (“TransMedics” or “the Company”) (NASDAQ: TMDX) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for al...
Themefolio
Profiler
Peergroup
© PR Newswire
27.02.2025
TMDX
LISTED
NASDAQ
TransMedics Reports Fourth Quarter and Full Year 2024 Financial Results
News Preview
ANDOVER, Mass., Feb. 27, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2024.
Recent Highligh...
Themefolio
Profiler
Peergroup
© BusinessWire
21.02.2025
TMDX
LISTED
NASDAQ
TMDX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that TransMedics Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against TransMedics Group, Inc. (“TransMedics” or “the Company”) (NASDAQ: TMDX) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for al...
Themefolio
Profiler
Peergroup
© BusinessWire
20.02.2025
TMDX
LISTED
NASDAQ
Class Action Announcement TMDX: A Securities Fraud Class Action Lawsuit Was Filed Against TransMedics Group, Inc. (TMDX) - Contact Kessler Topaz Meltzer & Check, LLP
News Preview
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against TransMedics Group, Inc. (“TransMedics”) (NASDAQ: TMDX) on behalf of those who purchased or otherwise acquired TransMedics securities between February 28, 2023, and January 10, 2025, inclusive (the “C...
Themefolio
Profiler
Peergroup
© BusinessWire
19.02.2025
TMDX
LISTED
NASDAQ
TMDX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that TransMedics Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of TransMedics Group, Inc. (NASDAQ: TMDX) publicly traded securities between February 28, 2023 and January 10, 2025, both dates inclusive (the “Class Period”), have until April 15, 2025 to seek appointment as lead plaintiff of the TransMedics class action l...
Themefolio
Profiler
Peergroup
© BusinessWire
19.02.2025
TMDX
LISTED
NASDAQ
TMDX ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of TransMedics Group, Inc. Investors
News Preview
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of those who acquired TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ:TMDX) securities during the period from February 28, 2023, through January 10, 2025 (“the Class Period...
Themefolio
Profiler
Peergroup
© PR Newswire
18.02.2025
TMDX
LISTED
NASDAQ
TransMedics to Present at Upcoming March Investor Conferences
News Preview
ANDOVER, Mass., Feb. 18, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management...
Themefolio
Profiler
Peergroup
© BusinessWire
18.02.2025
TMDX
LISTED
NASDAQ
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of TransMedics Group
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ: TMDX) and reminds investors of the April 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Fa...
Themefolio
Profiler
Peergroup
© BusinessWire
17.02.2025
TMDX
LISTED
NASDAQ
TMDX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that TransMedics Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of TransMedics Group, Inc. (NASDAQ: TMDX) publicly traded securities between February 28, 2023 and January 10, 2025, both dates inclusive (the “Class Period”), have until April 15, 2025 to seek appointment as lead plaintiff of the TransMedics class action l...
Themefolio
Profiler
Peergroup
© BusinessWire
15.02.2025
TMDX
LISTED
NASDAQ
TMDX Investors Have Opportunity to Lead TransMedics Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against TransMedics Group, Inc. (“TransMedics” or “the Company”) (NASDAQ: TMDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commissi...
Themefolio
Profiler
Peergroup
© BusinessWire
14.02.2025
TMDX
LISTED
NASDAQ
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of TransMedics Group, Inc. Investors – TMDX
News Preview
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of TransMedics Group, Inc. (NASDAQ: TMDX) between February 28, 2023 and January 10, 2025, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for TransMedics investors under the fede...
Themefolio
Profiler
Peergroup
© PR Newswire
03.02.2025
TMDX
LISTED
NASDAQ
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
ANDOVER, Mass., Feb. 3, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on January 28, 2025, TransMedics granted non-qualified stock options to purchase an aggrega...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2025
TMDX
LISTED
NASDAQ
NASDAQ: TMDX Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages TransMedics Group, Inc. (NASDAQ: TMDX) Investors with Significant Losses to Contact the Firm
News Preview
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of TransMedics Group, Inc. (NASDAQ: TMDX) (“TransMedics”).
On January 10, 2025, Scorpion Capital issued a short seller report on TransMedics. Specifically, the report alleged...
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2025
TMDX
LISTED
NASDAQ
TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Securities Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TransMedics Group, Inc. (“TransMedics” or “the Company”) (NASDAQ: TMDX) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or fa...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
TMDX
LISTED
NASDAQ
Rosen Law Firm Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation – TMDX
News Preview
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TransMedics Group, Inc. (NASDAQ: TMDX) resulting from allegations that TransMedics may have issued materially misleading business information to the investing public.
So What: If you purchased TransMedics...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2025
TMDX
LISTED
NASDAQ
TransMedics Responds to Inaccurate and Misleading Claims in Recent Short-Seller Report
News Preview
ANDOVER, Mass., Jan. 13, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Sco...
Themefolio
Profiler
Peergroup
© PR Newswire
23.12.2024
TMDX
LISTED
NASDAQ
TransMedics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
ANDOVER, Mass. , Dec. 23, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 43rd Annual J.P. Morgan Heal...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2024
TMDX
LISTED
NASDAQ
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
ANDOVER, Mass., Dec. 12, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on December 9, 2024, TransMedics granted non-qualified stock options to purchase an aggreg...
Themefolio
Profiler
Peergroup
© PR Newswire
02.12.2024
TMDX
LISTED
NASDAQ
TransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook
News Preview
ANDOVER, Mass., Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective Dec...
Themefolio
Profiler
Peergroup
© PR Newswire
26.11.2024
TMDX
LISTED
NASDAQ
TransMedics to Host Investor & Analyst Day on December 10, 2024
News Preview
ANDOVER, Mass., Nov. 26, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that it will host an Investor & Analyst Day in New York City on Tuesday, December 10, 2024,...
Themefolio
Profiler
Peergroup
© PR Newswire
19.11.2024
TMDX
LISTED
NASDAQ
TransMedics to Participate in the Piper Sandler 36th Annual Healthcare Conference
News Preview
ANDOVER, Mass., Nov. 19, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Piper S...
Themefolio
Profiler
Peergroup
© BusinessWire
08.11.2024
TMDX
LISTED
NASDAQ
Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into TransMedics Group, Inc. (NASDAQ: TMDX)
News Preview
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether TransMedics Group, Inc. (“TransMedics Group” or the “Company”) (NASDAQ: TMDX) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in vi...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2024
TMDX
LISTED
NASDAQ
TMDX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into TransMedics Group, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
News Preview
Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving TransMedics Group, Inc. (NASDAQ: TMDX) focused on whether the company and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.
If you have information th...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2024
TMDX
LISTED
NASDAQ
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
ANDOVER, Mass., Oct. 29, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 23, 2024, TransMedics granted non-qualified stock options to purchase an aggreg...
Themefolio
Profiler
Peergroup
© PR Newswire
28.10.2024
TMDX
LISTED
NASDAQ
TransMedics Reports Third Quarter 2024 Financial Results
News Preview
ANDOVER, Mass., Oct. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2024....
Themefolio
Profiler
Peergroup
© PR Newswire
15.10.2024
TMDX
LISTED
NASDAQ
TransMedics to Report Third Quarter 2024 Financial Results on October 28, 2024
News Preview
ANDOVER, Mass., Oct. 15, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2024 after market close on Monday,...
Themefolio
Profiler
Peergroup
© PR Newswire
27.09.2024
TMDX
LISTED
NASDAQ
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
ANDOVER, Mass., Sept. 27, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on September 24, 2024, TransMedics granted non-qualified stock options to purchase an agg...
Themefolio
Profiler
Peergroup
© PR Newswire
21.08.2024
TMDX
LISTED
NASDAQ
TransMedics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
ANDOVER, Mass., Aug. 21, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2024
TMDX
LISTED
NASDAQ
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
ANDOVER, Mass., Aug. 20, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on August 16, 2024, TransMedics granted non-qualified stock options to purchase an aggrega...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
